In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ValiRx PLC

www.valirx.com

Latest From ValiRx PLC

Pipeline Watch: Topline Readouts With Keytruda, Cosentyx And Zepsyre

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Trials In Prostate Cancer, Diffuse Large B-cell Lymphoma

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Pipeline Watch

AbbVie, Roche Claim Important Win For Venetoclax In CLL

Partners AbbVie and Roche's Genentech scored an important win for their B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in a Phase II clinical trial that met the study's primary endpoint in hard-to-treat chronic lymphocytic leukemia (CLL) patients, setting the stage for potential accelerated approval.

Cancer

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010

Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • ValiRx PLC
  • Senior Management
  • Satu Vainikka, PhD, CEO
    George Morris, PhD, Chief Dev. Officer
    Gerry Desler, Dir., Fin.
  • Contact Info
  • ValiRx PLC
    Phone: (44) 203 0084416
    24 Greville St.
    London, EC1N 8SS
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register